Pazopanib, trabectedin, or eribulin? Can immune-related markers dictate which to use in STS?

Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) may be used to indicate whether patients with soft tissue sarcomas (STSs) should receive pazopanib, trabectedin, or eribulin first, according to a study.
Pazopanib, trabectedin, and eribulin are often used for the treatment of STS although “there is little consensus on which agent should be preferentially used in a clinical setting,” according to the study authors.

In this study, 63 patients with advanced STS who were administered pazopanib, trabectedin, and eribulin were divided into groups according to which drug they were treated with first.

There was no significant difference in overall survival (OS) between the groups.

The OS of patients with low NLR first treated with pazopanib was shorter than the other groups.

The OS of patients with low PLR first treated with eribulin was longer than the other groups.

Reference
Shimada E, Endo M, Matsumoto, et al. Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients? J Clin Med. 2021;10(21):4972.